Literature DB >> 9135498

Co-ordinated changes in expression of cell adhesion molecules in prostate cancer.

S J Murant1, J Handley, M Stower, N Reid, O Cussenot, N J Maitland.   

Abstract

The expressions of E-cadherin, the integrin subunits beta 1, beta 2, beta 3, CD44 and alpha-catenin were studied in parallel by immunohistochemistry in a series of 40 prostate biopsies comprising one normal, 11 benign prostatic hyperplasia (BPH), and 28 prostatic adenocarcinomas. As reported by others, there was a consistent loss of E-cadherin expression with increasing tumour grade and de-differentiation. However, a significant proportion of losses occurred at earlier grades than previously reported. The parallel nature of this study showed, for the first time in human prostate carcinoma, a reciprocal expression pattern of E-cadherin and beta 1 integrin in the higher grades of prostate cancer. A reciprocal expression pattern was also found for E-cadherin and CD44 between moderately and poorly differentiated tumours. alpha-Catenin expression was downregulated only in those cells which had previously lost E-cadherin expression, and beta 2 and beta 3 integrin were rarely expressed in prostate tumours. A loss of expression of the luminal epithelial specific keratins CK8 and CK18 was also observed in advanced stage, poorly differentiated carcinomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135498     DOI: 10.1016/s0959-8049(96)00418-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  28 in total

1.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Authors:  Deborah A Bradley; Stephanie Daignault; Charles J Ryan; Robert S Dipaola; Kathleen A Cooney; David C Smith; Eric Small; Paul Mathew; Mitchell E Gross; Mark N Stein; Alice Chen; Kenneth J Pienta; June Escara-Wilke; Gerald Doyle; Mahmoud Al-Hawary; Evan T Keller; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-03-25       Impact factor: 3.850

Review 2.  Integrins in prostate cancer progression.

Authors:  Hira Lal Goel; Jing Li; Sophia Kogan; Lucia R Languino
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

3.  Screening biomarkers of prostate cancer by integrating microRNA and mRNA microarrays.

Authors:  Jiayu Feng; Chibing Huang; Xinwei Diao; Minqi Fan; Pingxian Wang; Ya Xiao; Xiao Zhong; Ronghua Wu
Journal:  Genet Test Mol Biomarkers       Date:  2013-08-28

4.  Pilot study on the effects of dietary conjugated linoleic acid on tumorigenesis and gene expression in PyMT transgenic mice.

Authors:  Margaret Flowers; Joyce A Schroeder; Alexander D Borowsky; David G Besselsen; Cynthia A Thomson; Ritu Pandey; Patricia A Thompson
Journal:  Carcinogenesis       Date:  2010-07-11       Impact factor: 4.944

5.  RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels.

Authors:  Constantinos G Broustas; Howard B Lieberman
Journal:  Prostate       Date:  2014-08-11       Impact factor: 4.104

6.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

Review 7.  Molecular mechanisms of metastasis in prostate cancer.

Authors:  Noel W Clarke; Claire A Hart; Mick D Brown
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

8.  Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion.

Authors:  Siyi Hu; Nathalie Delorme; Zhenzhen Liu; Tao Liu; Cruz Velasco-Gonzalez; Jone Garai; Ashok Pullikuth; Shahriar Koochekpour
Journal:  Mol Cancer       Date:  2010-02-04       Impact factor: 27.401

Review 9.  Prostate cancer regulatory networks.

Authors:  Dario C Altieri; Lucia R Languino; Jane B Lian; Janet L Stein; Irwin Leav; Andre J van Wijnen; Zhong Jiang; Gary S Stein
Journal:  J Cell Biochem       Date:  2009-08-01       Impact factor: 4.429

10.  Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo.

Authors:  Xueping Zhang; Marcia V Fournier; Joy L Ware; Mina J Bissell; Adly Yacoub; Zendra E Zehner
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.